Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review

被引：7

作者：

Wu, Jinchun ^{[1
]}

Liu, Yanmin ^{[1
]}

Wei, Xiaojuan ^{[1
]}

Zhang, Xiaofei ^{[1
]}

Ye, Yi ^{[2
]}

Li, Wei ^{[1
]}

Su, Xiaoling ^{[1
]}

机构：

[1] Qinghai Prov Peoples Hosp, Dept Cardiol, Xining, Peoples R China

[2] Qinghai Univ, Grad Sch, Xining, Peoples R China

来源：

FRONTIERS IN CARDIOVASCULAR MEDICINE | 2022年 / 9卷

关键词：

Na+ homeostasis; Ca2+ homeostasis; Na+-H+ exchanger regulatory factor (NHERF)1; 2; Na+-Ca2+ exchanger (NCX); ventricular arrhythmia (VAs); atrial fibrillation; arrhythmia; sodium-glucose cotransporter 2 inhibitor; SUDDEN CARDIAC DEATH; SGLT2; INHIBITORS; HEART-FAILURE; VENTRICULAR-ARRHYTHMIAS; DIASTOLIC DYSFUNCTION; ATRIAL-FIBRILLATION; ARTERIAL STIFFNESS; NA+/H+ EXCHANGER; BLOOD-PRESSURE; EMPAGLIFLOZIN;

D O I：

10.3389/fcvm.2022.915455

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a new type of oral hypoglycaemic agent with good cardiovascular protective effects. There are several lines of clinical evidence suggest that SGLT2i can significantly reduce the risks of heart failure, cardiovascular death, and delay the progression of chronic kidney disease. In addition, recent basic and clinical studies have also reported that SGLT2i also has good anti-arrhythmic effects. However, the exact mechanism is poorly understood. The aim of this review is to summarize recent clinical findings, studies of laboratory animals, and related study about this aspect of the antiarrhythmic effects of SGLT2i, to further explore its underlying mechanisms, safety, and prospects for clinical applications of it.

引用

页数：10

共 50 条

[21] Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Kuchay, Mohammad Shafi
Farooqui, Khalid Jamal
Mishra, Sunil Kumar
Mithal, Ambrish
DIABETES: FROM RESEARCH TO CLINICAL PRACTICE, VOL 4, 2021, 1307 : 213 - 230
[22] Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review
Tharmaraja, Thahesh
Ho, Jamie S. Y.
Sia, Ching-Hui
Lim, Nicole-Ann
Chong, Yao Feng
Lim, Amanda Y. L.
Rathakrishnan, Rahul R.
Yeo, Leonard L. L.
Sharma, Vijay K.
Tan, Benjamin Y. Q.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2022, 13
[23] The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
Wan, Ningning
Rahman, Asadur
Hitomi, Hirofurni
Nishiyama, Akira
FRONTIERS IN ENDOCRINOLOGY, 2018, 9
[24] Cardiovascular effects of sodium-glucose cotransporter 2 inhibitors: multiple actions
Wroblewski, Norman
CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (09) : 1515 - 1515
[25] The effects of sodium-glucose cotransporter 2 inhibitors on the 'forgotten' right ventricle
Qu, Liangzhen
Duan, Xueting
Chen, Han
ESC HEART FAILURE, 2025, 12 (02): : 1045 - 1058
[26] The pleiotropic cardiovascular effects of sodium-glucose cotransporter-2 inhibitors
Tanna, Monique S.
Goldberg, Lee R.
CURRENT OPINION IN CARDIOLOGY, 2021, 36 (06) : 764 - 768
[27] Heart and Sodium-Glucose Cotransporter 2 Inhibitors: A Sodium Dilemma
Oyesomi, Elizabeth T.
Tabrizchi, Reza
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2022, 79 (05) : 641 - 643
[28] Sodium-glucose cotransporter inhibitors for diabetes
Isaji, Masayuki
CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2007, 8 (04) : 285 - 292
[29] Sodium-glucose cotransporter inhibitors and kidney fibrosis: review of the current evidence and related mechanisms
Afsar, Baris
Afsar, Rengin Elsurer
PHARMACOLOGICAL REPORTS, 2023, 75 (01) : 44 - 68
[30] Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling
Husam M. Salah
Subodh Verma
Carlos G. Santos-Gallego
Ankeet S. Bhatt
Muthiah Vaduganathan
Muhammad Shahzeb Khan
Renato D. Lopes
Subhi J. Al’Aref
Darren K. McGuire
Marat Fudim
Journal of Cardiovascular Translational Research, 2022, 15 : 944 - 956

← 1 2 3 4 5 →